Head-To-Head Survey: Lyell Immunopharma (NASDAQ:LYEL) and ProKidney (NASDAQ:PROK)

ProKidney (NASDAQ:PROK) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ProKidney and Lyell Immunopharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1	1	1	1	2.50
Lyell Immunopharma	1	1	6	1	2.78

ProKidney currently has a consensus target price of $12.00, indicating a potential upside of 757.14%. Lyell Immunopharma has a consensus target price of $40.86, indicating a potential upside of 201.53%. Given ProKidney’s higher probable upside, equities analysts plainly believe ProKidney is more favorable than Lyell Immunopharma.

Insider and Institutional Ownership

51.6% of ProKidney shares are held by institutional investors. Comparatively, 66.0% of Lyell Immunopharma shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares ProKidney and Lyell Immunopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProKidney	-10,288.39%	N/A	-27.39%
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

Volatility & Risk

ProKidney has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500.

Earnings and Valuation

This table compares ProKidney and Lyell Immunopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890,000.00	475.56	-$68.99 million	($0.55)	-2.55
Lyell Immunopharma	$40,000.00	8,299.38	-$274.45 million	($12.83)	-1.06

ProKidney has higher revenue and earnings than Lyell Immunopharma. ProKidney is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Summary

ProKidney beats Lyell Immunopharma on 9 of the 14 factors compared between the two stocks.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

About Lyell Immunopharma

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.